These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 31775455)

  • 1. [The safety and efficacy of low dose subcutaneous decitabine combined with arsenic trioxide in patients with inermediate or higer-risk myelodysplastic syndrome].
    Ai H; Wei XD; Yin QS; Mi RH; Chen L; Wang Q; Song YP
    Zhonghua Nei Ke Za Zhi; 2019 Dec; 58(12):908-910. PubMed ID: 31775455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The clinical safety and efficacy of low dose subcutaneous decitabine in treating acute myeloid leukemia and intermediate- or higer-risk myelodysplastic syndromes in the elderly patients].
    Ai H; Wei XD; Yin QS; Wang P; Mi RH; Yuan FF; Chen L; Song YP
    Zhonghua Nei Ke Za Zhi; 2017 Aug; 56(8):606-609. PubMed ID: 28789495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decitabine shows synergistic effects with arsenic trioxide against myelodysplastic syndrome cells via endoplasmic reticulum stress-related apoptosis.
    Huang L; Liu Z; Jiang H; Li L; Fu R
    J Investig Med; 2019 Oct; 67(7):1067-1075. PubMed ID: 30898879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparison of clinical efficacy between decitabine combined with CAG regimen and CAG regimen alone in patients with intermediate to high-risk myelodysplastic syndromes].
    Zhang YP; Wu WZ; Cui GX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Oct; 22(5):1341-4. PubMed ID: 25338585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone-targeting nanoparticle to co-deliver decitabine and arsenic trioxide for effective therapy of myelodysplastic syndrome with low systemic toxicity.
    Wu X; Hu Z; Nizzero S; Zhang G; Ramirez MR; Shi C; Zhou J; Ferrari M; Shen H
    J Control Release; 2017 Dec; 268():92-101. PubMed ID: 29042320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decitabine improves overall survival in myelodysplastic syndromes-RAEB patients aged ≥60 years and has lower toxicities: Comparison with low-dose chemotherapy.
    Ye L; Ren Y; Zhou X; Mei C; Xu W; Ma L; Luo Y; Hu C; Ye X; Wei J; Lou Y; Jin J; Tong H
    Blood Cells Mol Dis; 2019 Jul; 77():88-94. PubMed ID: 31005752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decitabine in the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes, Which Combined with Complex Karyotype Respectively.
    Gao S; Li Z; Fu JH; Hu XH; Xu Y; Jin ZM; Tang XW; Han Y; Chen SN; Sun AN; Wu DP; Qiu HY
    Asian Pac J Cancer Prev; 2015; 16(15):6627-32. PubMed ID: 26434886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical Efficacy Comparison of Ultralow Dose of Decitabine and Cyclosporine on Low-risk and Intermediate-risk Type 1 of Myelodysplastic Syndrome].
    Luo X; Wu H; Ding Y; Chen YH; Liang AB
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Apr; 24(2):510-4. PubMed ID: 27151020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Retrospective efficacy analysis of decitabine bridging allogeneic hematopoietic stem cell transplantation on the treatment of myelodysplastic syndrome].
    Zheng H; Wang J; Zhou J; Wang P; Fu C; Wu D; Sun A; Qiu H; Jin Z; Han Y; Tang X; Ma X
    Zhonghua Xue Ye Xue Za Zhi; 2015 Feb; 36(2):121-4. PubMed ID: 25778887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effects of Low-Dose Decitabine on Soluble CD44, GDF11 Levels and Hematopoietic Function in Elderly Patients with MDS].
    Guo SQ; Shi R; Chen YY; Liu S; Li YH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Apr; 27(2):509-514. PubMed ID: 30998162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical Efficacy and Prognostic Factors of Decitabine for Treatment of Myelodysplastic Syndrome].
    Bao ZH; Zhao HG; Yu HE
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Dec; 26(6):1702-1707. PubMed ID: 30501707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical Efficacy of Low-dose Decitabine Combined with CAG Regimen in Patients with Myelodysplastic Syndrome-refractory Anemia with Excess Blasts(MDS-RAEB)].
    Wang M; Han HH; Guo R; Liu YF; Jiang ZX; Sun H
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Oct; 25(5):1482-1486. PubMed ID: 29070129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure.
    Harel S; Cherait A; Berthon C; Willekens C; Park S; Rigal M; Brechignac S; Thépot S; Quesnel B; Gardin C; Adès L; Fenaux P; Braun T
    Leuk Res; 2015 May; 39(5):501-4. PubMed ID: 25735917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy and toxicity of the CHG priming regimen (low-dose cytarabine, homoharringtonine, and G-CSF) in higher risk MDS patients relapsed or refractory to decitabine.
    Xiu C; Li X; Wu L; Xu F; He Q; Zhang Z; Wu D; Song L; Su J; Zhou L; Zhao Y; Tao Y; Chang C
    J Cancer Res Clin Oncol; 2019 Dec; 145(12):3089-3097. PubMed ID: 31559495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of decitabine-combined minimally myelosuppressive regimen bridged allo-HSCT on the outcomes of pediatric MDS from 10 years' experience of a single center.
    Gao J; Hu Y; Gao L; Xiao P; Lu J; Hu S
    BMC Pediatr; 2022 May; 22(1):312. PubMed ID: 35624441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Very-low-dose decitabine treatment for patients with intermediate- or high-risk myelodysplastic syndrome: a retrospective analysis of thirteen cases.
    Zhang K; Lian Y; Guan X; Hu Q; Lei L; Tao L; He D; Lin J; Hou Z; Ren L; Liu X; Ren Q; Pan L; Fei X; Xiong M; Wen S; Cao J
    Ann Hematol; 2020 Nov; 99(11):2539-2546. PubMed ID: 32939674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparison of Decitabine Rigimen and Traditional Chemotherapy Regimen in Treatment of Patients with Intermediate or High-Risk Myelodysplastic Syndrome].
    Zhang QP; Han YS; Wan X; Sun GY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Feb; 26(1):197-201. PubMed ID: 29397843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical Efficacy of Low-Dose Decitabine alone for Treatment of Myelodysplastic Syndrome].
    Shi R; Guo SQ; Chen YY; Liu S; Li YH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Oct; 27(5):1568-1573. PubMed ID: 31607313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Significance of Platelet Recovery in Myelodysplastic Syndromes With Severe Thrombocytopenia.
    Tang Y; Zhang X; Han S; Chu T; Qi J; Wang H; Tang X; Qiu H; Fu C; Ruan C; Wu D; Han Y
    Clin Appl Thromb Hemost; 2018 Dec; 24(9_suppl):217S-222S. PubMed ID: 30296835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes.
    Schiller GJ; Slack J; Hainsworth JD; Mason J; Saleh M; Rizzieri D; Douer D; List AF
    J Clin Oncol; 2006 Jun; 24(16):2456-64. PubMed ID: 16651647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.